Literature DB >> 25941581

Chemoimmunotherapy targeting Wilms' tumor 1 (WT1)-specific cytotoxic T lymphocyte and helper T cell responses for patients with pancreatic cancer.

Shigeo Koido1, Sadamu Homma2, Masato Okamoto3, Kazuki Takakura4, Jianlin Gong5, Haruo Sugiyama6, Toshifumi Ohkusa4, Hisao Tajiri4.   

Abstract

We designed a phase 1 study using dendritic cells (DCs) pulsed with a mixture of three types of Wilms' tumor 1 (WT1) peptides, including MHC class I/II restricted epitopes (DC/WT1-I/II). Our recent work reveals that the combination of DC/WT1-I/II and chemotherapy induced long-term WT1-specific CD4+ and CD8+ T cell responses.

Entities:  

Keywords:  MHC class II; WT1; dendritic cell; helper T cell

Year:  2014        PMID： 25941581      PMCID： PMC4292571          DOI： 10.4161/21624011.2014.958950

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity.

Authors:  A L Marzo; B F Kinnear; R A Lake; J J Frelinger; E J Collins; B W Robinson; B Scott
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

2.  CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity.

Authors:  I F Hermans; D S Ritchie; J Yang; J M Roberts; F Ronchese
Journal:  J Immunol       Date:  2000-03-15       Impact factor: 5.422

3.  Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.

Authors:  Naomi N Hunder; Herschel Wallen; Jianhong Cao; Deborah W Hendricks; John Z Reilly; Rebecca Rodmyre; Achim Jungbluth; Sacha Gnjatic; John A Thompson; Cassian Yee
Journal:  N Engl J Med       Date:  2008-06-19       Impact factor: 91.245

4.  Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response.

Authors:  Akitaka Takahara; Shigeo Koido; Masaki Ito; Eijiro Nagasaki; Yukiko Sagawa; Takeo Iwamoto; Hideo Komita; Toshiki Ochi; Hiroshi Fujiwara; Masaki Yasukawa; Junichi Mineno; Hiroshi Shiku; Sumiyuki Nishida; Haruo Sugiyama; Hisao Tajiri; Sadamu Homma
Journal:  Cancer Immunol Immunother       Date:  2011-05-24       Impact factor: 6.968

5.  Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer.

Authors:  Miho Kaida; Yuriko Morita-Hoshi; Atsuko Soeda; Takako Wakeda; Yuni Yamaki; Yasushi Kojima; Hideki Ueno; Shunsuke Kondo; Chigusa Morizane; Masafumi Ikeda; Takuji Okusaka; Yoichi Takaue; Yuji Heike
Journal:  J Immunother       Date:  2011-01       Impact factor: 4.456

6.  Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer.

Authors:  Shigeo Koido; Sadamu Homma; Masato Okamoto; Kazuki Takakura; Masako Mori; Shinji Yoshizaki; Shintaro Tsukinaga; Shunichi Odahara; Seita Koyama; Hiroo Imazu; Kan Uchiyama; Mikio Kajihara; Hiroshi Arakawa; Takeyuki Misawa; Yoichi Toyama; Satoru Yanagisawa; Masahiro Ikegami; Shin Kan; Kazumi Hayashi; Hideo Komita; Yuko Kamata; Masaki Ito; Takefumi Ishidao; Sei-Ichi Yusa; Shigetaka Shimodaira; Jianlin Gong; Haruo Sugiyama; Toshifumi Ohkusa; Hisao Tajiri
Journal:  Clin Cancer Res       Date:  2014-07-23       Impact factor: 12.531

7.  Tumor regression by CD4 T-cells primed with dendritic/tumor fusion cell vaccines.

Authors:  Shigeo Koido; Yutaka Enomoto; Vasso Apostolopoulos; Jianlin Gong
Journal:  Anticancer Res       Date:  2014-08       Impact factor: 2.480

8.  The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.

Authors:  Martin A Cheever; James P Allison; Andrea S Ferris; Olivera J Finn; Benjamin M Hastings; Toby T Hecht; Ira Mellman; Sheila A Prindiville; Jaye L Viner; Louis M Weiner; Lynn M Matrisian
Journal:  Clin Cancer Res       Date:  2009-09-01       Impact factor: 12.531

9.  Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer.

Authors:  Sumiyuki Nishida; Shigeo Koido; Yutaka Takeda; Sadamu Homma; Hideo Komita; Akitaka Takahara; Satoshi Morita; Toshinori Ito; Soyoko Morimoto; Kazuma Hara; Akihiro Tsuboi; Yoshihiro Oka; Satoru Yanagisawa; Yoichi Toyama; Masahiro Ikegami; Toru Kitagawa; Hidetoshi Eguchi; Hiroshi Wada; Hiroaki Nagano; Jun Nakata; Yoshiki Nakae; Naoki Hosen; Yusuke Oji; Toshio Tanaka; Ichiro Kawase; Atsushi Kumanogoh; Junichi Sakamoto; Yuichiro Doki; Masaki Mori; Toshifumi Ohkusa; Hisao Tajiri; Haruo Sugiyama
Journal:  J Immunother       Date:  2014 Feb-Mar       Impact factor: 4.456

10.  Targeting PD-1/PD-L1 interactions for cancer immunotherapy.

Authors:  Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2012-11-01       Impact factor: 8.110
  10 in total
  4 in total

Review 1.  Dendritic cell-based cancer immunotherapy for colorectal cancer.

Authors:  Mikio Kajihara; Kazuki Takakura; Tomoya Kanai; Zensho Ito; Keisuke Saito; Shinichiro Takami; Shigetaka Shimodaira; Masato Okamoto; Toshifumi Ohkusa; Shigeo Koido
Journal:  World J Gastroenterol       Date:  2016-05-07       Impact factor: 5.742

Review 2.  Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancer.

Authors:  Mikio Kajihara; Kazuki Takakura; Tomoya Kanai; Zensho Ito; Yoshihiro Matsumoto; Shigetaka Shimodaira; Masato Okamoto; Toshifumi Ohkusa; Shigeo Koido
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

3.  Prognostic significance of Wilms' tumor 1 expression in patients with pancreatic ductal adenocarcinoma.

Authors:  Tomoya Kanai; Zensho Ito; Yusuke Oji; Machi Suka; Sumiyuki Nishida; Kazuki Takakura; Mikio Kajihara; Masayuki Saruta; Shuichi Fujioka; Takeyuki Misawa; Tadashi Akiba; Hiroyuki Yanagisawa; Shigetaka Shimodaira; Masato Okamoto; Haruo Sugiyama; Shigeo Koido
Journal:  Oncol Lett       Date:  2018-06-13       Impact factor: 2.967

4.  Prognostic value of immune factors in the tumor microenvironment of patients with pancreatic ductal adenocarcinoma.

Authors:  Sachie Kiryu; Zensho Ito; Machi Suka; Tsuuse Bito; Shin Kan; Kan Uchiyama; Masayuki Saruta; Taigo Hata; Yuki Takano; Shuichi Fujioka; Takeyuki Misawa; Takashi Yamauchi; Hiroyuki Yanagisawa; Nobuhiro Sato; Toshifumi Ohkusa; Haruo Sugiyama; Shigeo Koido
Journal:  BMC Cancer       Date:  2021-11-10       Impact factor: 4.430
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.